Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss

Sylvia M Brakenhoff, Robert A de Man, André Boonstra, Margo J H van Campenhout, Robert J de Knegt, Florian van Bömmel, Annemiek A van der Eijk, Thomas Berg, Bettina E Hansen, Harry L A Janssen, Milan J Sonneveld, Sylvia M Brakenhoff, Robert A de Man, André Boonstra, Margo J H van Campenhout, Robert J de Knegt, Florian van Bömmel, Annemiek A van der Eijk, Thomas Berg, Bettina E Hansen, Harry L A Janssen, Milan J Sonneveld

Abstract

Background: Serum hepatitis B virus (HBV) RNA may reflect intrahepatic HBV replication. Novel anti-viral drugs have shown potent HBV RNA decline without concomitant hepatitis B surface antigen (HBsAg) decrease. How this relates to off-treatment response is yet unclear.

Aim: To study the degree of on-treatment viral antigen decline among patients with pronounced HBV RNA decrease in relation to off-treatment sustained response and HBsAg loss.

Methods: HBV RNA, HBsAg and hepatitis B core-related antigen (HBcrAg) were quantified in patients with chronic hepatitis B who participated in two randomised controlled trials of peginterferon-based therapy. Sustained response (HBV DNA <2000 IU/mL) and/or HBsAg loss were assessed in patients with and without on-treatment HBV RNA response (either >2 log HBV RNA decline or >1 log decline resulting in an undetectable value at on-treatment week 24), stratified by concomitant HBsAg decline (<0.5/0.5-1/>1 log).

Results: We enrolled 279 patients; 176 were hepatitis B e antigen (HBeAg)-positive, and 103 were HBeAg-negative. Sustained response was achieved in 20.4% of patients. At on-treatment week 24, HBV RNA response was associated with higher sustained response rates (27.4% vs 13.0% in non-responders, P = 0.004). However, among patients with an HBV RNA response (n = 135), 56.4% did not experience >0.5 log HBsAg decline. Among HBV RNA responders, sustained response was achieved in 47.6% of those with >1 log HBsAg decline (n = 20/42), vs 16.0% with <0.5 log decline (n = 12/75, P = 0.001). Similar results were obtained with HBcrAg and when response was defined as HBsAg loss.

Conclusions: In this cohort, many patients with HBV RNA response during peginterferon-based treatment did not experience HBsAg and/or HBcrAg decline. The absence of concomitant decline in these viral antigens was associated with low rates of treatment response and HBsAg loss. Future trials should therefore consider kinetics of combined biomarkers to assess anti-viral efficacy. Trial registration, ClinicalTrials.gov: NCT00114361, NCT00146705.

© 2020 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.

Figures

FIGURE 1
FIGURE 1
(A) Rates of sustained response (HBV DNA 1 log). HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus
FIGURE 2
FIGURE 2
(A) Hepatitis B surface antigen (HBsAg) decline during treatment and follow‐up in patients with an hepatitis B virus (HBV) RNA response at on‐treatment week 24, stratified by patients with and without sustained response (HBV DNA P‐value for comparison at week 24. BL, baseline; EOF, end of follow‐up; EOT, end of treatment; HBcrAg, hepatitis B core‐related antigen; HBsAg, hepatitis B surface antigen; SR, sustained response; wk, week
FIGURE 3
FIGURE 3
(A) Rates of sustained response (HBV DNA 3 log). Assessed in patients with positive HBeAg at baseline. HBcrAg, hepatitis B core‐related antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus

References

    1. World Health Organization . Hepatitis B factsheet. 2019, updated 18–07‐2019 [Access Date 18–05‐2020].
    1. Martinez MG, Testoni B, Zoulim F. Biological basis for functional cure of chronic hepatitis B. J Viral Hepat. 2019;26:786‐794.
    1. Petersen J, Thompson AJ, Levrero M. Aiming for cure in HBV and HDV infection. J Hepatol. 2016;65:835‐848.
    1. Lucifora J, Protzer U. Attacking hepatitis B virus cccDNA–the holy grail to hepatitis B cure. J Hepatol. 2016;64:S41‐S48.
    1. Kostyusheva A, Kostyushev D, Brezgin S, Volchkova E, Chulanov V. Clinical implications of hepatitis B Virus RNA and covalently closed circular DNA in monitoring patients with chronic hepatitis B today with a gaze into the future: the field is unprepared for a sterilizing cure. Genes (Basel). 2018;9:483.
    1. Buti M, Riveiro‐Barciela M, Esteban R. Long‐term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38:84‐89.
    1. Lopatin U. Drugs in the pipeline for HBV. Clin Liver Dis. 2019;23:535‐555.
    1. Jeng WJ, Sheen IS, Chen YC, et al. Off‐therapy durability of response to entecavir therapy in hepatitis B e antigen‐negative chronic hepatitis B patients. Hepatology. 2013;58:1888‐1896.
    1. Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: a systematic review. Hepatology. 2016;63:1481‐1492.
    1. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha‐2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006;44:675‐684.
    1. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa‐2a, lamivudine, and the combination for HBeAg‐positive chronic hepatitis B. N Engl J Med. 2005;352:2682‐2695.
    1. Zhou Y, Yan R, Ru GQ, Yu LL, Yao J, Wang H. Pegylated‐interferon consolidation treatment versus nucleos(t)ide analogue consolidation treatment in non‐cirrhotic hepatitis B patients with hepatitis B e antigen seroconversion: an open‐label pilot trial. Hepatol Int. 2019;13:422‐430.
    1. Yuen MF, Gane EJ, Kim DJ, et al. Antiviral activity, safety, and pharmacokinetics of capsid assembly modulator NVR 3–778 in patients with chronic HBV infection. Gastroenterology. 2019;156:1392‐1403.e7.
    1. Bazinet M, Pantea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa‐2a in patients with chronic HBV infection naive to nucleos(t)ide therapy. Gastroenterology. 2020;158:2180‐2194.
    1. Liu Y, Jiang M, Xue J, Yan H, Liang X. Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterol. 2019;19:53.
    1. Giersch K, Allweiss L, Volz T, Dandri M, Lutgehetmann M. Serum HBV pgRNA as a clinical marker for cccDNA activity. J Hepatol. 2017;66:460‐462.
    1. Wang J, Yu Y, Li G, et al. Natural history of serum HBV‐RNA in chronic HBV infection. J Viral Hepat. 2018;25:1038‐1047.
    1. van Bommel F, van Bommel A, Krauel A, et al. Serum HBV RNA as a predictor of peginterferon alfa‐2a response in patients with HBeAg‐positive chronic hepatitis B. J Infect Dis. 2018;218:1066‐1074.
    1. van Bömmel F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66‐76.
    1. Luo H, Tan N, Kang Q, et al. HBV pgRNA status can reveal the long‐term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat. 2020;27:323‐328.
    1. Huang YW, Takahashi S, Tsuge M, et al. On‐treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy. Antivir Ther. 2015;20:369‐375.
    1. Jansen L, Kootstra NA, van Dort KA, Takkenberg RB, Reesink HW, Zaaijer HL. Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa‐2a and nucleos(t)ide analogues. J Infect Dis. 2016;213:224‐232.
    1. Farag MS, van Campenhout MJH, Pfefferkorn M, et al. Hepatitis B virus RNA as early predictor for response to PEGylated interferon alfa in HBeAg negative chronic hepatitis B. Clin Infect Dis. 2020: ciaa013. 10.1093/cid/ciaa013.
    1. Campenhout MJH, Bömmel F, Pfefferkorn M, et al. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg‐positive chronic hepatitis B. J Viral Hepat. 2020;27:610‐619.
    1. Yuen M‐F, Agarwal K, Gane EJ, et al. Safety, pharmacokinetics, and antiviral effects of ABI‐H0731, a hepatitis B virus core inhibitor: a randomised, placebo‐controlled phase 1 trial. Lancet Gastroenterol Hepatol. 2020;5:152‐166.
    1. Sonneveld MJ. Core inhibitor therapy for chronic hepatitis B. Lancet Gastroenterol Hepatol. 2020;5:99‐100.
    1. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa‐2b alone or in combination with lamivudine for HBeAg‐positive chronic hepatitis B: a randomised trial. Lancet. 2005;365:123‐129.
    1. Rijckborst V, ter Borg MJ, Cakaloglu Y, et al. A randomized trial of peginterferon alpha‐2a with or without ribavirin for HBeAg‐negative chronic hepatitis B. Am J Gastroenterol. 2010;105:1762‐1769.
    1. van Campenhout MJH, van Bommel F, Pfefferkorn M, et al. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology. 2018;68:839‐847.
    1. Campenhout MJH, Rijckborst V, Brouwer WP, et al. Hepatitis B core‐related antigen monitoring during peginterferon alfa treatment for HBeAg‐negative chronic hepatitis B. J Viral Hepat. 2019;26:1156‐1163.
    1. Datta S, Chatterjee S, Veer V, Chakravarty R. Molecular biology of the hepatitis B virus for clinicians. J Clin Exp Hepatol. 2012;2:353‐365.
    1. Diab A, Foca A, Zoulim F, Durantel D, Andrisani O. The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: implications for the development of HBc‐targeting antivirals. Antiviral Res. 2018;149:211‐220.
    1. Luo H, Tan N, Kang Q, et al. Hepatitis B virus pregenomic RNA status can reveal the long‐term prognoses of chronic hepatitis B patients treated with nucleos(t)ide analogues. J Viral Hepat. 2020;27:323‐328.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere